The Therapeutic System: Therapeutic Implications of Rate-Controlled Drug Delivery

  • John Urquhart
Part of the Experimental Biology and Medicine book series (EBAM, volume 7)

Abstract

The concept of the therapeutic system (Anonymous, 1970, 1971; Heilmann, 1982) brought Tak Higuchi and Alex Zaffaroni together in a day-to-day working collaboration that continued for over 4 years between 1969 and 1972. Higuchi’s laboratory played a major role in developing the first two therapeutic system products, which have embodied a number of pharmaceutical “firsts”. These are the pilocarpine ocular therapeutic system and the progesterone uterine therapeutic system.

Keywords

Toxicity Progesterone Salicylate Valproate Toxicology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anonymous, Towards a new concept of precision in drug administration. Pharm. J., 205 (1970) 400–402.Google Scholar
  2. Anonymous, ALZA’s approach to controlled medication. Pharm. J., 207 (1971) 414–415.Google Scholar
  3. Bergqvist, A. and Rybo, G., Treatment of menorrhagia with intrauterine release of progesterone. Br. J. Obstet. Gynaecol., 90 (1983) 255–258.PubMedCrossRefGoogle Scholar
  4. Carlson, R. W. and Sikic, B. I., Continuous infusion or bolus injection in cancer chemotherapy. Ann. Intern. Med., 99 (1983) 823–833.PubMedGoogle Scholar
  5. Fara, J. and Urquhart, J., The value of infusion and injec–tion regimens in assessing efficacy and toxicity of drugs. Trends Pharmacol. Sci., 5 (1984) 21–25.CrossRefGoogle Scholar
  6. Heilmann, K., Therapeutische Systeme-Konzept und Realisation programmierter Arzneiverabreichung. 2. uberarbeitete und erweiterte Auflage, Ferdinand Enke Verlag, Stuttgart, 1982.Google Scholar
  7. Higuchi, T., Leeper, H. M., and Theeuwes, F., U.S. Patent 3,995,631, Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient, issued 7 December 1976.Google Scholar
  8. Knobil, E., The neuroendocrine control of the menstrual cycle. Rec. Prog. Horm. Res., 36 (1980) 53–88.PubMedGoogle Scholar
  9. Nau, H., Merker, H. J., Brendel, K., Gansau, C., Häuser, I., and Wittfoht, W., Disposition, embryotoxicity, and teratogenicity of valproic acid in the mouse as related to man. In Levy, R. H., Ritlick, W. H., Eichelbaum, M., and Meijer, J. (Eds) Metabolism of Antiepileptic Drugs, Raven Press, New York, 1984, pp. 85–96.Google Scholar
  10. Nau, H., Zierer, R., Spielmann, H., Neubert, D., and Gansau, C., A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci., 29 (1981) 2803–2813.PubMedCrossRefGoogle Scholar
  11. Osieka, V. R., Continuous infusion vs. bolus injection of bleomycin in a human testicular cancer xenograft system. Arzneim. Forsch., 34 (1984) 460–464.Google Scholar
  12. Pizarro, E., Gomez-Rogers, C., and Rowe, P. J., A comparative study of the effect of the PROGESTASERT and GRAVIGARD IUDs on dysmenorrhoea. Contraception, 20 (1979) 455–466.PubMedCrossRefGoogle Scholar
  13. Shaw, J. and Urquhart, J., Programmed systemic drug delivery by the transdermal route. Trend Pharmacol. Sci., 1 (1980) 208–211.CrossRefGoogle Scholar
  14. Sikic, B. I., Collins, J. M., Mimnaugh, E. G., and Gram, T. E., Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat. Rep., 62 (1978) 2011–2017.PubMedGoogle Scholar
  15. Theeuwes, F. and Yum, S. I., Principles of the design and operation of generic osmotic pumps for the delivery ofGoogle Scholar
  16. semisolid or liquid drug formulations. Ann. Biomed. Eng., 4 (1976) 343–353.PubMedCrossRefGoogle Scholar
  17. Urquhart, J., Endocrinology and the systems paradigm. Behay. Sci., 15 (1970) 57–71.CrossRefGoogle Scholar
  18. Urquhart, J., Opportunities for research: methods of drug administration. In Proceedings of the Institute of Medicine Conference on Pharmaceuticals for Developing Countries, National Academy of Sciences, Washington, D. C., 1979, pp. 329–348.Google Scholar
  19. Urquhart, J., Development of the OCUSERT pilocarpine ocular therapeutic systems-a case history in ophthalmic product development. In Robinson, J. (Ed) Ophthalmic Drug Delivery Systems, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington, D. C., 1980, pp. 105–118.Google Scholar
  20. Urquhart, J., Performance requirements for controlled—release dosage forms: therapeutic and pharmacological perspectives. In Urquhart, J. (Ed) Controlled—Release Pharmaceuticals, American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington, D. C., 1981, pp. 1–48.Google Scholar
  21. Urquhart, J., Drug development and preclinical research applications of steady—state pharmacology. In Prescott, L. F. and Nimmo, W. S. (Eds) Rate Control in Drug Therapy, Churchill Livingstone, Edinburgh, 1985, pp. 19–29.Google Scholar
  22. Urquhart, J., Fara, J., and Willis, K. L., Rate—controlled delivery systems in drug and hormone research. Ann. Rev. Pharmacol. Toxicol., 24 (1984) 199–236.CrossRefGoogle Scholar
  23. Volpe, A., Botticelli, A., Abrate, M., Vecchia, E. D., Mantovani, M., Carani, C., Grasso, A., Mazza, V., and Di Renzo, G. C., An intrauterine progesterone contraceptive system (52 mg) used in pre— and pert—menopausal patients with endometrial hyperplasia. Maturitas, 4 (1982) 73–79.PubMedCrossRefGoogle Scholar

Copyright information

© The Humana Press Inc. 1985

Authors and Affiliations

  • John Urquhart
    • 1
  1. 1.ALZA CorporationPalo AltoUSA

Personalised recommendations